A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Ipilimumab (Primary)
- Indications Carcinoma; Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.